CONTEXT: Aging in men is associated with reduced testosterone (T) levels and physiological changes leading to frailty, but the benefits of T supplementation are inconclusive. OBJECTIVE: We studied the effects of T supplementation with and without progressive resistance training (PRT) on functional performance, strength, and body composition. DESIGN, SETTING, AND PARTICIPANTS: We recruited 167 generally healthy community-dwelling older men (66 ± 5 years) with low-normal baseline total T levels (200-350 ng/dL). INTERVENTION: Subjects were randomized to placebo or transdermal T gel [2 doses targeting either a lower (400-550 ng/dL) or higher (600-1000 ng/dL) T range] and to either PRT or no exercise for 12 months. MAIN OUTCOME MEASURE: The primary outcome was functional performance, whereas secondary outcomes were strength and body composition. RESULTS: A total of 143 men completed the study. At 12 months, total T was 528 ± 287 ng/dL in subjects receiving any T and 287 ± 65 ng/dL in the placebo group. In the PRT group, function and strength were not different between T- and placebo-treated subjects, despite greater improvements in fat mass (P = .04) and fat-free mass (P = .01) with T. In the non-PRT group, T did not improve function but improved fat mass (P = .005), fat-free mass (P = .03), and upper body strength (P = .03) compared with placebo. There were fewer cardiovascular events in the T-treated groups compared with placebo. CONCLUSIONS:T supplementation was well tolerated and improved body composition but had no effect on functional performance. T supplementation improved upper body strength only in nonexercisers compared with placebo.
RCT Entities:
CONTEXT: Aging in men is associated with reduced testosterone (T) levels and physiological changes leading to frailty, but the benefits of T supplementation are inconclusive. OBJECTIVE: We studied the effects of T supplementation with and without progressive resistance training (PRT) on functional performance, strength, and body composition. DESIGN, SETTING, AND PARTICIPANTS: We recruited 167 generally healthy community-dwelling older men (66 ± 5 years) with low-normal baseline total T levels (200-350 ng/dL). INTERVENTION: Subjects were randomized to placebo or transdermal T gel [2 doses targeting either a lower (400-550 ng/dL) or higher (600-1000 ng/dL) T range] and to either PRT or no exercise for 12 months. MAIN OUTCOME MEASURE: The primary outcome was functional performance, whereas secondary outcomes were strength and body composition. RESULTS: A total of 143 men completed the study. At 12 months, total T was 528 ± 287 ng/dL in subjects receiving any T and 287 ± 65 ng/dL in the placebo group. In the PRT group, function and strength were not different between T- and placebo-treated subjects, despite greater improvements in fat mass (P = .04) and fat-free mass (P = .01) with T. In the non-PRT group, T did not improve function but improved fat mass (P = .005), fat-free mass (P = .03), and upper body strength (P = .03) compared with placebo. There were fewer cardiovascular events in the T-treated groups compared with placebo. CONCLUSIONS: T supplementation was well tolerated and improved body composition but had no effect on functional performance. T supplementation improved upper body strength only in nonexercisers compared with placebo.
Authors: R S Schwartz; W P Shuman; V L Bradbury; K C Cain; G W Fellingham; J C Beard; S E Kahn; J R Stratton; M D Cerqueira; I B Abrass Journal: J Gerontol Date: 1990-11
Authors: Charles P Lambert; Dennis H Sullivan; Scott A Freeling; Diana M Lindquist; William J Evans Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: Thomas G Travison; Shehzad Basaria; Thomas W Storer; Alan M Jette; Renee Miciek; Wildon R Farwell; Karen Choong; Kishore Lakshman; Norman A Mazer; Andrea D Coviello; Philip E Knapp; Jagadish Ulloor; Anqi Zhang; Brad Brooks; Ahn-Hoa Nguyen; Richard Eder; Nathan LeBrasseur; Ayan Elmi; Erica Appleman; Leife Hede-Brierley; Geeta Bhasin; Ashmeet Bhatia; Antonio Lazzari; Samuel Davis; Pengsheng Ni; Lauren Collins; Shalender Bhasin Journal: J Gerontol A Biol Sci Med Sci Date: 2011-06-22 Impact factor: 6.053
Authors: Tom E Nightingale; Pamela Moore; Joshua Harman; Refka Khalil; Ranjodh S Gill; Teodoro Castillo; Robert A Adler; Ashraf S Gorgey Journal: J Spinal Cord Med Date: 2017-08-03 Impact factor: 1.985
Authors: Thomas W Storer; Shalender Bhasin; Thomas G Travison; Karol Pencina; Renee Miciek; Jennifer McKinnon; Shehzad Basaria Journal: J Clin Endocrinol Metab Date: 2016-04-06 Impact factor: 5.958
Authors: Carolina G Fritsch; Maurício P Dornelles; Juliana L Teodoro; Larissa X N da Silva; Marco A Vaz; Ronei S Pinto; Eduardo L Cadore; Bruno M Baroni Journal: Eur J Appl Physiol Date: 2018-10-26 Impact factor: 3.078
Authors: Samantha Huo; Anthony R Scialli; Sean McGarvey; Elizabeth Hill; Buğra Tügertimur; Alycia Hogenmiller; Alessandra I Hirsch; Adriane Fugh-Berman Journal: PLoS One Date: 2016-09-21 Impact factor: 3.240